Abstract:The onset of cancer is a complex process that is driven by the accumulation of multiple genetic mutations. However, the fact that inhibition of a single oncogene can impair the proliferation and survival of cancer cells due to their "oncogene addiction" provides implications for the so-called "molecular targeted therapy" in cancer treatment. The oncogenic transcription factor c-Myc is overexpressed in many types of cancers, and as a typical oncogene to which many cancers are addicted, c-Myc is necessary for the rapid proliferation of cancer cells. Strategies aimed at targeting c-Myc, including interfering with c-Myc synthesis, stability and transcriptional activity, have emerged as effective cancer treatments. We have recently shown that a natural agent, oridonin, promotes the Fbw7-mediated proteasomal degradation of c-Myc, leading to subsequent cell growth inhibition and apoptosis and demonstrating a new c-Myc-targeting strategy. Despite the effectiveness of molecular targeting in cancer treatment, failure to achieve long-lasting efficacy with a single agent is observed because cancer cells can recover from oncogene addiction as a result of their genomic instability and heterogeneity. Combined cancer therapies were therefore developed and showed better efficacies than single-agent therapy in cancer cell lines and mouse models. Combined therapy based on c-Myc targeting can be achieved through various strategies. Agents that also target c-Myc but use different mechanisms, or agents that act on other genes in the c-Myc pathway, can be selected for combination. In addition, the targeting of genes involved in different cellular processes in other pathways might also be a successful strategy. Regardless of the therapy adopted, it is important to first determine the molecular mechanisms underlying the agents to inform the therapy design. Among the various targets of therapeutic agents is a family of noncoding small RNAs, called microRNAs, that have been implicated in the anti-cancer activity of many therapeutic agents. c-Myc, as a transcription factor, regulates the expression of many microRNAs and is in turn regulated by microRNAs. Combining c-Myc-targeting agents with those that target microRNAs might provide a novel approach for cancer therapy.

MYC in Liver Cancer: Mechanisms and Targeted Therapy Opportunities

Research Progress on Cancer-Associated Fibroblasts in Hepatocellular Carcinoma

MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products

Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Targeting oncogenic Myc as a strategy for cancer treatment

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

Alternative approaches to target Myc for cancer treatment

Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma

<p>Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives</p>

c-MYC—Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease

Targeting the mechano-microenvironment and liver cancer stem cells: a promising therapeutic strategy for liver cancer

Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer.

Myelocytomatosis‐Protein Arginine N‐Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma

Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer

MYC: there is more to it than cancer

Intricate effects of post-translational modifications in liver cancer: mechanisms to clinical applications

The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma

Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review

Attacking C-Myc: Targeted and Combined Therapies for Cancer.

Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies

Advances in the Study of Liver Cancer Stem Cells